A Phase 3 interventional study of Ivermectin and Diethylcarbamazine in Lymphatic Filariasis, sponsored by Washington University School of Medicine. Completed at 1 site in Côte d’Ivoire. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Washington University School of Medicine · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
This study will test the hypothesis that Moxidectin combination therapies are superior to ivermectin combination therapies for achieving sustained clearance of W. bancrofti microfilaremia.
This trial is designed as single-site, Phase III, randomized, open-label, masked-observer superiority trial with four treatment arms: ivermectin + albendazole (IA), moxidectin + albendazole (MoxA), ivermectin + diethylcarbamazine + albendazole (IDA), and moxidectin + diethylcarbamazine + albendazole (MoxDA). The primary endpoint is the proportion of participants achieving complete clearance of microfilaremia at 12 months (IA vs. MoxA comparison) or 24 months (IDA vs. MoxDA comparison). Block randomization by gender will be used to assign treatment arms.
The first 48 participants (12 each arm) will be treated at Agboville Hospital in Cote d'Ivoire at the Centre de Recherche de Filariose with inpatient AE monitoring and collection of post-treatment plasma drug levels (Part 1). For Part 1, active AE surveillance will be conducted in the hospital on days 1, 2, and 3, post-treatment, and in the participant's village of residence on day 7 post-treatment and passive surveillance will be conducted by trained village health workers on days 4-6. An interim safety analysis will take place after Part 1. If no safety concerns are identified, the remainder of the participants will be treated in their home villages, with active AE monitoring on days 1 and 2 post-treatment (Part 2) with passive surveillance by trained village health workers on days 3-7. Any participant in either Part 1 or Part 2 experiencing AEs of grade 2 or higher will be followed until adverse event (AE) severity falls below grade 2. Follow-up assessments for efficacy of treatments for all participants (Parts 1 and 2) will be conducted at 6, 12, 24, and 36 months.
The study includes both safety and efficacy analyses. The safety assessment (Part 1 only) ends 7 days after treatment (unless AEs remain grade 2 or higher). The efficacy assessment (Parts 1 and 2 combined) ends when participants are retested for filarial infection 36 months post-treatment. Participants in the IA arm will receive IA annually (standard of care). Participants in the other arms will receive the assigned treatment at baseline; those found to be microfilaremic at 24 months post-treatment will be retreated with the same treatment received at baseline. If clearance of microfilariae (Mf) at 12 months in the IA arm is superior to Mf clearance in the MoxA arm, the MoxA group will be switched to annual IA treatment.
The study design does not currently include stratification, nor do any sub-studies. However, the study may stratify based on pre-treatment Mf levels if high variability among pre-screening Mf counts is observed.
42 studies on the registry are indexed under Elephantiasis, Filarial; 5 are open to participants now.
This study's enrollment of 164 is below the median of 1,000 across 27 interventional studies indexed under Elephantiasis, Filarial.
Browse Elephantiasis, Filarial studies →Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one oral dose of Ivermectin (IVM) 200 µg/kg + Albendazole (ABZ) 400 mg (IA) annually for 24 months.
Drug: Ivermectin · Drug: Albendazole
Participants will receive one oral dose of Mox 8 mg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxA at the same dosage.
Drug: Albendazole · Drug: Moxidectin
Participants will receive one oral dose of IVM 200 µg/kg + Diethylcarbamazine (DEC) 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with IDA at the same dosage.
Drug: Ivermectin · Drug: Diethylcarbamazine · Drug: Albendazole
Participants will receive one oral dose of Mox 8 mg + DEC 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxDA at the same dosage.
Drug: Diethylcarbamazine · Drug: Albendazole · Drug: Moxidectin
Ivermectin (IVM) 200 µg/kg
Also known as: Stromectol
Diethylcarbamazine (DEC) 6mg/kg
Also known as: Diethylcarbamazine citrate, Hetrazan
Albendazole (ABZ) 400 mg
Moxidectin (Mox) 8 mg
Clearance of Microfilaremia (IA vs. MoxA)
The proportion of participants in IA and MoxA study arms with complete clearance of W. bancrofti microfilaremia at 12 months after treatment.
Time frame: 12 months
Clearance of Microfilaremia (IDA vs. MoxDA)
The proportion of participants in IDA and MoxDA study arms with complete clearance of W. bancrofti microfilaremia at 24 months after treatment.
Time frame: 24 months
Clearance of Microfilaremia
The proportion of participants in each study arm with complete clearance of W. bancrofti microfilaremia at 6, 12, 24, \& 36 months after treatment.
Time frame: 6, 12, 24, & 36 months
Change in Mf Counts
Change in microfilariae counts (relative to baseline) at12 \& 24 months
Time frame: Assessed at Baseline, 6, 12, & 24 months; Reported at 12 and 24 months
Reduction in Circulating Filarial Antigen (CFA) Counts
Reduction in circulating filarial antigen (CFA) counts (relative to baseline) at 12 \& 24 months
Time frame: Assessed at Baseline, 6, 12, & 24 months; 12 and 24 months reported
Inactivation of Adult Worm Nests in Male Participants Only
Inactivation of adult worm nests as assessed by scrotal ultrasound at 6, 12, and 24 months after treatment in male participants only
Time frame: 6, 12, & 24 months
Frequency and Severity of AEs
Frequency and severity of AEs during the first 7 days after treatment.
Time frame: From baseline treatment to 7 days post-treatment
Plasma Levels of Drugs/Metabolites Post Treatment
Noncompartmental pharmacokinetic analyses of DEC, ABZ, ABZSO, ABZSO2, IVM and Mox concentrations will be conducted using WinNonlin (Pharsight Corporation; Cary, North Carolina, USA). Drug plasma concentrations and computed pharmacokinetic parameters will be listed by subject and summarized by drug or metabolite (geometric mean with coefficient of variation, arithmetic mean with standard deviation, minimum, maximum, number of observations). Individual and geometric mean (by time) concentrations versus time will be plotted for each treatment group on both linear and natural logarithm scales.
Time frame: Baseline, 2, 3, 4, 6, 12, 24, & 48 hours post-treatment
| Milestone | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| Started | 41 | 40 | 41 | 42 |
| Completed | 25 | 16 | 22 | 23 |
| Not completed | 16 | 24 | 19 | 19 |
The proportion of participants in IA and MoxA study arms with complete clearance of W. bancrofti microfilaremia at 12 months after treatment.
| Participants | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| Clearance of Microfilaremia (IA vs. MoxA) | 8 | 18 | 24 | 27 |
The proportion of participants in IDA and MoxDA study arms with complete clearance of W. bancrofti microfilaremia at 24 months after treatment.
| Participants | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| Clearance of Microfilaremia (IDA vs. MoxDA) | 13 | 14 | 20 | 21 |
The proportion of participants in each study arm with complete clearance of W. bancrofti microfilaremia at 6, 12, 24, \& 36 months after treatment.
| Participants | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| 6 months | 8 | 15 | 20 | 24 |
| 12 months | 8 | 18 | 24 | 27 |
| 24 months | 13 | 14 | 20 | 21 |
| 36 months | 22 | 20 | 30 | 32 |
Change in microfilariae counts (relative to baseline) at12 \& 24 months
| Mf/mL | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| 12 Months | 20.70 (12.10 to 35.40) | 0.48 (0.07 to 3.10) | 1.30 (0.46 to 3.40) | 0.05 (0.01 to 0.42) |
| 24 Months | 8.10 (3.10 to 21.40) | 2.50 (0.57 to 10.60) | 2.00 (0.32 to 12.70) | 0.70 (0.12 to 4.20) |
Reduction in circulating filarial antigen (CFA) counts (relative to baseline) at 12 \& 24 months
| ng/mL | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| 12 Months | 21.70 (13.60 to 34.60) | 12.50 (7.30 to 21.40) | 10.30 (6.60 to 16.20) | 7.80 (4.80 to 12.60) |
| 24 Months | 12.16 (7.53 to 19.65) | 6.38 (3.7 to 11.01) | 5.14 (3.16 to 8.69) | 4.76 (2.89 to 7.84) |
Inactivation of adult worm nests as assessed by scrotal ultrasound at 6, 12, and 24 months after treatment in male participants only
| Participants | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| 12 Months | 1 | 7 | 10 | 10 |
| 24 Months | 4 | 8 | 7 | 12 |
Frequency and severity of AEs during the first 7 days after treatment.
| Participants | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| Frequency and Severity of AEs | 22 | 24 | 18 | 15 |
Noncompartmental pharmacokinetic analyses of DEC, ABZ, ABZSO, ABZSO2, IVM and Mox concentrations will be conducted using WinNonlin (Pharsight Corporation; Cary, North Carolina, USA). Drug plasma concentrations and computed pharmacokinetic parameters will be listed by subject and summarized by drug or metabolite (geometric mean with coefficient of variation, arithmetic mean with standard deviation, minimum, maximum, number of observations). Individual and geometric mean (by time) concentrations versus time will be plotted for each treatment group on both linear and natural logarithm scales.
| ng*hr/mL | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| ALB | 116.2 (10 to 686.3) | 172.1 (8 to 648.7) | 124.2 (9.9 to 366.2) | 82.4 (12.9 to 386.6) |
| ALB-OX | 3302.3 (1355.5 to 11146.8) | 4078.9 (897.4 to 5738.5) | 3512.5 (1264.8 to 9680.3) | 2595.8 (897.4 to 5738.5) |
| ALB-ON | 187.3 (43.2 to 593.9) | 300.8 (89.2 to 775) | 217.1 (79.5 to 613.5) | 174 (89.4 to 466.2) |
| DEC | — | — | 21308.2 (11177.4 to 28869.3) | 19544.9 (12412.9 to 28740.7) |
| IVM | 1505.1 (606.5 to 3318.4) | — | 1690.9 (885.5 to 3222.2) | — |
| MOX | — | 2530.8 (549.2 to 5933.8) | — | 2653.2 (993.5 to 7507.8) |
Collected over Active adverse event monitoring took place from treatment to 7 days post-treatment. Passive adverse event monitoring continued through 36-months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IA (Ivermectin + Albendazole) | 0/41 (0%) | 0/41 (0%) | 22/41 (53.7%) |
| MoxA (Moxidectin + Albendazole) | 2/40 (5%) | 2/40 (5%) | 24/40 (60%) |
| IDA (Ivermectin + Diethylcarbamazine + Albendazole) | 2/41 (4.9%) | 2/41 (4.9%) | 18/41 (43.9%) |
| MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) | 0/42 (0%) | 0/42 (0%) | 15/42 (35.7%) |
| Event | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| DeathGeneral disorders | 0/41 | 1/40 | 2/41 | 0/42 |
| SeizureGeneral disorders | 0/41 | 1/40 | 0/41 | 0/42 |
| Event | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) |
|---|---|---|---|---|
| Muscle or Joint PainGeneral disorders | 5/41 | 11/40 | 5/41 | 5/42 |
| HeadacheGeneral disorders | 9/41 | 4/40 | 3/41 | 5/42 |
| Itching SkinGeneral disorders | 2/41 | 7/40 | 0/41 | 2/42 |
| Abdominal PainGastrointestinal disorders | 7/41 | 2/40 | 4/41 | 2/42 |
| DiarrheaGeneral disorders | 5/41 | 3/40 | 3/41 | 4/42 |
| Dizziness, giddiness, or faintingGeneral disorders | 5/41 | 1/40 | 1/41 | 4/42 |
| NauseaGeneral disorders | 0/41 | 0/40 | 3/41 | 1/42 |
| Testicular or Scrotal PainGeneral disorders | 0/41 | 0/40 | 3/41 | 3/42 |
| OtherGeneral disorders | 0/41 | 0/40 | 3/41 | 1/42 |
| FatigueGeneral disorders | 1/41 | 2/40 | 0/41 | 1/42 |
| Age, Categorical(Participants) | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 29 | 22 | 32 | 30 | 113 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) | Total |
|---|---|---|---|---|---|
| Mean | 34.6 ± 10.6 | 37.3 ± 10.2 | 38.3 ± 11.9 | 39.7 ± 11.8 | 37 ± 11.2 |
| Sex: Female, Male(Participants) | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 2 | 4 | 10 |
| Male | 27 | 20 | 30 | 26 | 103 |
| Race and Ethnicity Not Collected(Participants) | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) | Total |
|---|---|---|---|---|---|
| Count of participants | — | — | — | — | 0 |
| Region of Enrollment(participants) | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) | Total |
|---|---|---|---|---|---|
| Côte D'Ivoire | 29 | 22 | 32 | 30 | 113 |
| Blood microfilaria count, median (IQR)(Mf/mL) | IA (Ivermectin + Albendazole) | MoxA (Moxidectin + Albendazole) | IDA (Ivermectin + Diethylcarbamazine + Albendazole) | MoxDA (Moxidectin + Diethylcarbamazine + Albendazole) | Total |
|---|---|---|---|---|---|
| Median | 342 (147 to 595) | 134 (98 to 318) | 204.5 (94 to 510.5) | 191.5 (83 to 312) | 209 (98 to 408) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified datasets used for published results will be shared publically through a journal or other open source data repository so that the broader scientific community can access it. Datasets used for published results will be shared publically through a journal or other open source data repository so that the broader scientific community can access it. Only de-identified data will be shared outside of the study team.
Ran from Aug 2020 to primary completion in Oct 2024, 49 months.
Results were first posted in Jan 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ivermectin · Diethylcarbamazine · Moxidectin
Washington University School of Medicine →